BioDuro, a global contract research, development and manufacturing organization, has formed an agreement with Porton Pharma Solutions, a provider of custom, cross life-cycle active pharmaceutical ingredient (API) development and cGMP manufacturing services to the global drug industry.

Under this agreement, BioDuro will promote and market Porton’s capabilities for pilot and large-scale GMP production of custom APIs and drug intermediates, while Porton will incorporate BioDuro’s array of technologies and resources in drug discovery, including lead compound ID, lead optimization and clinical candidate nomination. It will also utilize BioDuro’s expert formulations development and cGMP manufacture of clinical trial materials into Porton’s suite of solutions to address complex process scale-up challenges for IND-enabling studies.

“Our partnership with Porton further expands the reach of our offerings to provide fully integrated API and drug product development and manufacturing solutions to our clients for seamless advancement of their programs from discovery to clinical development,” said Cyrus Mirsaidi, president and chief executive officer, BioDuro. “Porton’s global footprint and proven track record with many of the world’s leading pharmaceutical companies will provide substantiated channels for timely and reliable delivery of high value therapeutics, using innovative and cost effective manufacturing routes, backed by high-quality assets in Asia and North America.”

Oliver Ju, chief executive officer, Porton, said, “We are very excited about our collaboration with BioDuro as we complement each other’s capabilities and share an industry reputation for scientific and technical expertise, excellence in operational performance and a client-centric culture. Together, we can offer our global customers compelling benefits in the form of robustly integrated solutions, compressed drug development timelines and a highly efficient supply chain across the product life cycle.”